Financials data is unavailable for this security.
View more
Year on year Shield Therapeutics PLC grew revenues 137.95% from 5.50m to 13.09m while net income improved from a loss of 49.79m to a smaller loss of 33.29m.
Gross margin | 30.78% |
---|---|
Net profit margin | -254.44% |
Operating margin | -239.44% |
Return on assets | -88.29% |
---|---|
Return on equity | -308.60% |
Return on investment | -136.30% |
More ▼
Cash flow in GBPView more
In 2023, Shield Therapeutics PLC increased its cash reserves by 309.99%, or 10.55m. Cash Flow from Financing totalled 49.66m or 379.49% of revenues. In addition the company used 37.13m for operations while cash used for investing totalled 2.43m.
Cash flow per share | -0.0446 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0192 |
---|---|
Tangible book value per share | -0.0023 |
More ▼
Balance sheet in GBPView more
Current ratio | 2.28 |
---|---|
Quick ratio | 2.04 |
Total debt/total equity | 1.35 |
---|---|
Total debt/total capital | 0.5739 |
More ▼